Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks

20250 citationsJournal Articlehybrid Open Access

Authors

Juliette Jacquot-Thierry · Sorbonne Université

Sarah Chalopin · Inserm

Héléna Mosbah · Centre Hospitalier Universitaire de Poitiers

Émilie Montastier · Hôpital Rangueil

Fabien Mourre · Hôpital Marin de Hendaye

Blandine Gatta‐Cherifi · Inserm

Julien Bourry ·

Abstract

SGLT2is improve glycemic control and renal markers in PWS with no weight loss. Close safety monitoring is warranted, particularly regarding renal function in PWS and more generally towards all complex obesity with neurodevelopmental disorders.

Topics & Keywords

Genetic Syndromes and Imprinting Pancreatic function and diabetes Diabetes Treatment and Management

Publication Details

Published in: Diabetes & Metabolism

Volume 51, Issue 6, pp. 101704-101704

DOI: 10.1016/j.diabet.2025.101704

Field-Weighted Citation Impact: 0.00

Command Palette

Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks

Authors

Abstract

Topics & Keywords

Publication Details